The assesment of the effects of omega 3 faty acid supplementation on serum level of Omentin , Chemerin and TNF-alpha in patients with type 2 diabetes mellitus
Objective: The effect of omega 3 fatty acids supplementation in adult with type 2 of diabetes mellitus Study design Randomized, double-blind, placebo-controlled, single-center, trial study (phase II) population: Adults with Type 2 Diabetes Referring to the Iranian Diabetes Center inclusion criteria: 30-65 years of age, T2DM diagnosis, and BMI in the range of 18.5 to 40 kg/m2 exclusion criteria: Unwillingness to cooperate, change the dose or type of anti-diabetes drug, incidence of any sensitivity Interventions: omega 3 supplementation and placebo Intervention period: 10 weeks outcomes: plasma levels of omentin, chemerin and TNF-a
General information
Acronym
IRCT registration information
IRCT registration number:IRCT2017092724081N3
Registration date:2017-11-01, 1396/08/10
Registration timing:retrospective
Last update:
Update count:0
Registration date
2017-11-01, 1396/08/10
Registrant information
Name
Niaz Mohammadzade Honarvar
Name of organization / entity
Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 8897 4461
Email address
honarvar@tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Tehran university of medical sciences
Expected recruitment start date
2012-01-01, 1390/10/11
Expected recruitment end date
2012-05-01, 1391/02/12
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The assesment of the effects of omega 3 faty acid supplementation on serum level of Omentin , Chemerin and TNF-alpha in patients with type 2 diabetes mellitus
Public title
The effects of omega-3 fatty acids supplementation on type 2 diabetes mellitus
Purpose
Supportive
Inclusion/Exclusion criteria
The criteria for inclusion were as follows: 30-65 years of age; T2DM diagnosis; and BMI in the range of 18.5 to 40 kg/m2. Patients with a history of diseases including chronic renal; hepatic; gastrointestinal; hematological diseases; and thyroid disorder as well as pregnant and lactating patients were excluded from the study. Furthermore, Patients who were treated with insulin; Thiazolidinediones or consumed weight loss drugs and any nutritional supplement 2 weeks prior to the beginning of the study were excluded from the study.
The exclusion criteria: Unwillingness to cooperate; change the dose or type of anti-diabetes drug; incidence of any sensitivity Interventions.
Age
From 40 years old to 65 years old
Gender
Both
Phase
2-3
Groups that have been masked
No information
Sample size
Target sample size:
20
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethic committee of Tehran university of medical sciences